Stockholm Life Tech vital to Flemingsberg’s development

Flemingsberg Science is an active part of Stockholm Life Tech. It develops new opportunities for collaboration and co-operation related to Flemingsberg’s research and innovation infrastructure.

The Life Science Strategy for the Stockholm Region states that “the life science industry is of vital importance for the commercialisation and application of research and innovation breakthroughs for the benefit of inhabitants.”

Johnny Högberg, CEO, Flemingsberg Science

The Stockholm Life Tech project is one of the ongoing initiatives aimed at developing the life science sector in the Stockholm region. The project is of interest and importance for Flemingsberg and Flemingsberg Science from several perspectives.

Firstly, it is a regional initiative in which Flemingsberg Science, together with project participants Region Stockholm, Akademiska Hus, Karolinska Institutet, KI Science Park, Karolinska University Hospital and Stockholm Science City work to support the development of the industry. Through the project, Flemingsberg Science becomes part of and co-creator of the goal that Region Stockholm 2025 will be one of the five leading life science clusters in the world.

Furthermore, the project enables the development of Flemingsberg’s research and innovation infrastructure (FOII). The project supports and simplifies opportunities for companies such as Vecura and ANA Futura to collaborate with small and medium-sized enterprises (SMEs) by developing different forms of co-operation and agreements, for example. This drives increased interest in Flemingsberg and the FOIIs from SMEs, and increases opportunities for more start-ups and growth in Flemingsberg, which is also in line with Flemingsberg Science’s new strategic objectives.

There are already SMEs that collaborate with ANA Futura and Vecura. One example is Biomedrex, which is based in ANA Futura; another is XNK Therapeutics, which has worked with Vecura for a number of years.

Johnny Högberg, CEO, Flemingsberg Science

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Kick-off Cluster Engine Life Science Flemingsberg!

At the end of last year, the Flemingsberg Science Foundation was granted funding from the European Regional Development Fund (ERDF) for the project Cluster Engine Life Science Flemingsberg, which aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. Recently, it was time for the official launch – and what a grand launch it was!

Flemingsberg Expands with Huge Bostäder

Imagine a home where The Royal Swedish Opera and The Royal Dramatic Theatre’s studios are in your front yard, and the Flemingsberg Forest Nature Reserve and Lake Gömmaren are in your back yard. Where Campus Flemingsberg is your neighbor to the left, and a modernized shopping center your neighbor to the right. Too good to be true? Not at all!